Whether you choose a single GLP-1 agent or the GLP-Squared dual-compound protocol, your physician can coordinate timing and dosing to minimize interactions with spironolactone
These medications can delay gastric emptying, increasing aspiration risks during anesthesia, which requires special precautions
Weight management (and the treatment of weight-related comorbidities) is not one-size-fits-all
Report any changes in vision immediately, including blurriness, dark spots, pain, or loss of vision in one eye
Mounjaro and Vision Changes 2026 Update July 2026: There are currently 146 pending claims in the MDL for patients alleging that GLP-1 drugs, including Mounjaro, led them to develop NAION (vision loss)
Most European health systems are publicly funded and must evaluate obesity drugs through a strict cost-effectiveness lens